128 related articles for article (PubMed ID: 30253908)
21. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
22. Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors.
Shah AH; Kuchakulla M; Ibrahim GM; Dadheech E; Komotar RJ; Gultekin SH; Ivan ME
World Neurosurg; 2019 Jan; 121():e836-e842. PubMed ID: 30312826
[TBL] [Abstract][Full Text] [Related]
23. Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
Heßelmann V; Mager AK; Goetz C; Detsch O; Theisgen HK; Friese M; Schwindt W; Gottschalk J; Kremer P
Rofo; 2017 Jun; 189(6):519-526. PubMed ID: 28591887
[No Abstract] [Full Text] [Related]
24. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Franceschi E; Lamberti G; Visani M; Paccapelo A; Mura A; Tallini G; Pession A; De Biase D; Minichillo S; Tosoni A; Di Battista M; Cubeddu A; Bartolini S; Brandes AA
Future Oncol; 2018 May; 14(11):1063-1069. PubMed ID: 29741106
[TBL] [Abstract][Full Text] [Related]
26. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
27. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
[TBL] [Abstract][Full Text] [Related]
28. Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.
Thomas JG; Rao G; Kew Y; Prabhu SS
Neurosurg Focus; 2016 Oct; 41(4):E12. PubMed ID: 27690657
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
30. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
31. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
32. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
[TBL] [Abstract][Full Text] [Related]
33. The value of
Garcia JR; Cozar M; Baquero M; Fernández Barrionuevo JM; Jaramillo A; Rubio J; Maida G; Soler M; Riera E
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):85-90. PubMed ID: 27503425
[TBL] [Abstract][Full Text] [Related]
34. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib in glioblastoma recurrence: A case report.
Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
37. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Brandes AA; Tosoni A; Franceschi E; Sotti G; Frezza G; Amistà P; Morandi L; Spagnolli F; Ermani M
J Clin Oncol; 2009 Mar; 27(8):1275-9. PubMed ID: 19188675
[TBL] [Abstract][Full Text] [Related]
38. FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment.
Leiva-Salinas C; Schiff D; Flors L; Patrie JT; Rehm PK
Radiology; 2017 May; 283(2):508-514. PubMed ID: 28234553
[TBL] [Abstract][Full Text] [Related]
39. Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Perry LA; Korfiatis P; Agrawal JP; Erickson BJ
Neuroradiology; 2018 Jan; 60(1):35-42. PubMed ID: 29103145
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
